Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, last year, the company brought in $3.2 billion in revenue, compared to more ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business ...

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...

The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu ...

Shares of several vaccine makers soared after reports suggest that the Biden administration is in discussions with Moderna MRNA and Pfizer PFE to set up a possible vaccine program aimed at ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.